Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease with limited treatment options that can progress to more severe forms of liver damage such as cirrhosis or hepatocellular carcinoma. Targeting peroxisome proliferator-activated receptors (PPARs) with compounds such as elafibranor (GFT-505) is a feasible strategy for the prevention and treatment of NASH.
Terns Pharmaceuticals Inc.’s unveiled positive top-line data from the phase IIa Duet study testing TERN-501, an oral thyroid hormone receptor-beta (THR-B) agonist, given as a monotherapy or in combination with TERN-101, a liver-distributed farnesoid X receptor agonist, for the treatment of nonalcoholic steatohepatitis (NASH).
Researchers from Hepagene Therapeutics Inc. have disclosed preclinical data for the novel FXR agonist HPG-1860, which is being developed for the treatment of nonalcoholic steatohepatitis (NASH).
Two biopharma companies entered the public markets on July 14, with Apogee Therapeutics Inc. pricing a $300 million IPO, the second largest U.S. debut this year, and Sagimet Biosciences Inc. raising $85 million. Apogee, of San Francisco, and Waltham, Mass., is advancing APG-777 and APG-808, which are in development for atopic dermatitis (AD) and chronic obstructive pulmonary disease, while San Mateo, Calif.-based Sagimet’s lead candidate is the FASN inhibitor denifanstat for nonalcoholic steatohepatitis.
Researchers from Gat Therapeutics SL reported preclinical data for GTX-011, a first-in-class anti-inflammatory and antifibrotic drug candidate with properties mediated by the inhibition of the TGF-β pathway.
Three years after stopping development in nonalcoholic steatohepatitis, Genfit SA and partner Ipsen Pharma SA have announced positive phase III data for elafibranor in the treatment of primary biliary cholangitis (PBC) and are preparing to file for U.S. FDA and EMA approval.
Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease, where in addition to the accumulation of fat in the liver, there is also chronic inflammation and hepatocyte injury. With no therapy approved yet, selective thyroid hormone receptor-β (THR-β) agonism has yielded good results in ongoing clinical development.
Primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) are chronic inflammatory liver diseases. It is known that one of the cell signaling molecules overexpressed in the liver during inflammation is IL-18, which is also a marker of hepatocyte injury and liver steatosis.
Intercept Pharmaceuticals Inc.’s second attempt to score an expanded U.S. FDA approval of its farnesoid X receptor agonist, obeticholic acid, in patients with non-alcoholic steatohepatitis (NASH) went the way of the first, with the agency issuing another complete response letter (CRL), prompting the company to drop all NASH-related investment and cut a third of its workforce.
At the ongoing EASL meeting, researchers from Hepagene Therapeutics Inc. presented preclinical data for the novel thyroid hormone receptor β (THR-β) agonist HPG-7233, being developed for the treatment of nonalcoholic steatohepatitis (NASH).
